During the launch of Bevacizumab, a biosimilar of Avastin, Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd stated that one of the problems they were trying to solve was to disrupt the cost barriers in the biosimilars market because India has been developing biosimilars for quite some time but the affordability has remained a big concern.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/TY6CWON
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Enzene Biosciences announces India launch of colorectal cancer drug Bevacizumab
https://ift.tt/tpJb54w
No comments:
Post a Comment